Product image of Latanotears (Latanoprost) supplied by GNH India

Latanotears

Active Ingredient:
Latanoprost
Origin:
EU

Latanotears (Latanoprost)

Latanoprost, the active ingredient in Latanotears, is a prostaglandin analog presented as an ophthalmic solution for ocular use. It is employed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension, helping to preserve visual function.

GNH India supplies Latanotears as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. Our supply chain ensures product integrity from manufacturing to end‑user, and we provide comprehensive documentation and support for regulatory compliance in each market we serve.

Manufacturer / TM Owner

Aurobindo N.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Latanoprost is a prostaglandin analog used to manage ocular pressure in glaucoma and ocular hypertension.
  • Open‑angle glaucoma: reduces intra‑ocular pressure, thereby slowing optic nerve damage and visual field loss in patients with primary open‑angle glaucoma.
  • Ocular hypertension: lowers elevated intra‑ocular pressure, helping to prevent progression to glaucoma in patients diagnosed with ocular hypertension.
  • Pseudoexfoliative glaucoma: increases uveoscleral outflow to control pressure in pseudoexfoliative (secondary open‑angle) glaucoma, aiding in disease management.
  • Normal‑tension glaucoma: provides pressure reduction that may benefit patients with normal‑tension glaucoma.

How It Works

  • Latanoprost is a synthetic analogue of prostaglandin F2α that binds to FP receptors on the ciliary muscle. Activation of these receptors remodels the extracellular matrix, enhancing uveoscleral outflow of aqueous humor. The increased outflow reduces intra‑ocular pressure without affecting aqueous humor production, providing effective pressure control in glaucoma and ocular hypertension.

Side Effects

Latanotears may cause ocular and systemic adverse reactions, most of which are mild and transient.

Common Side Effects

  • Eye redness: mild conjunctival hyperemia.
  • Eye itching or irritation: transient discomfort.
  • Increased brown pigmentation of the iris: gradual darkening.
  • Eyelash growth: longer, thicker lashes.

Serious or Rare Side Effects

  • Severe ocular inflammation: uveitis or iritis.
  • Corneal edema: swelling of the cornea.
  • Vision loss: sudden decrease in visual acuity.

Precautions & Warnings

Before initiating Latanotears, clinicians should consider several safety measures.

  • Baseline assessment: assess baseline intra‑ocular pressure before therapy.
  • Monitoring: monitor intra‑ocular pressure regularly after starting treatment.
  • Infection risk: avoid use in patients with active ocular infection.
  • Pigmentation changes: inform patients about possible iris color change and that it may be permanent.
  • Discontinue if severe inflammation occurs.
  • Store at room temperature: keep in the original container, protect from light and moisture.

Avoid Interactions

Latanotears can interact with other ophthalmic agents, requiring careful management.

Major Interactions (Avoid)

  • Concurrent use with other prostaglandin analogs: may increase risk of ocular side effects.
  • Combination with carbonic anhydrase inhibitors: additive intra‑ocular pressure lowering effect may cause hypotony.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory eye drops: may reduce efficacy of Latanotears.
  • Beta‑blocker eye drops: additive pressure‑lowering effect, monitor IOP.
  • Systemic prostaglandin analogs: potential for increased systemic effects.

Frequently Asked Questions

Latanotears is an ophthalmic solution containing latanoprost, prescribed to lower intra‑ocular pressure in patients with open‑angle glaucoma or ocular hypertension. By reducing pressure, it helps to slow disease progression and protect visual function.

Latanoprost mimics prostaglandin F2α and binds to FP receptors on the ciliary muscle. This triggers remodeling of the extracellular matrix, enhancing uveoscleral outflow of aqueous humor, which lowers intra‑ocular pressure without affecting fluid production.

The dosing regimen for Latanotears is determined by the prescribing clinician. Typically, one drop is instilled in the affected eye(s) once daily, but the exact dose and timing should follow the prescriber’s instructions.

Safety data for latanoprost during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk. Patients who are pregnant, planning pregnancy, or breastfeeding should discuss use with their healthcare provider.

To order Latanotears, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and import documentation.

Latanotears belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intra‑ocular pressure reduction. Compared with alternatives such as beta‑blocker eye drops, it has a different side‑effect profile, including potential iris darkening, but often provides greater pressure‑lowering efficacy.

Latanotears should be stored at room temperature, protected from light and moisture, and kept in its original container. Do not freeze the product. If the solution appears discolored or contains particles, it should not be used.

Latanotears is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and instill one drop into the conjunctival sac. Close the eye gently for a few seconds and avoid blinking excessively.

Serious risks include severe ocular inflammation such as uveitis or iritis, corneal edema, and rare cases of sudden vision loss. If any of these occur, the medication should be discontinued immediately and the patient evaluated by an eye specialist.

Latanotears should not be used by individuals with known hypersensitivity to latanoprost or any component of the formulation, patients with active ocular infections, or those with severe ocular inflammation without prior medical advice. Contraindications should be confirmed by a qualified eye care professional.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Latanoprost

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT